Search Results 871-880 of 11117 for SC
This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107 administered every 28 days (4 ...
... SC, Orme JJ, Mateo J, Agarwal N, Gillessen S, Murad MH, Sartor O, Bryce AH. Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic ...
The primary study hypothesis is that pembrolizumab will provide a clinically meaningful overall response rate. A Study of SC-006 in Subjects With Advanced ...
The Copland Cancer Biology and Translational Research Lab at Mayo Clinic has created novel SCD1-specific inhibitors that are being developed for cancer ...
Kowalchuk RO, Lester SC, Graham RP, Harmsen WS, Zhang L, Halfdanarson TR, Smoot RL, Gits HC, Ma WW, Owen D, Mahipal A, Miller RC, Wittich MAN, Cleary SP ...
Olivia Sirpilla, Ph.D. student in Molecular Pharmacology and Experimental Therapeutics at Mayo Clinic, researches stem cells as a therapy for immune ...
... SC, Walker L, Wolff D, Yared JA, Schoemans H, Tichelli A. Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic ...
A Clinical Study of the Modified Thread Carpal Tunnel Release. Guo D. Danqing; Guo D. Danzhu; Guo J. Joseph; Schmidt SC. Steven C; Lytie RM. Rachel M. Hand ...
The purpose of this study is to determine the best noninvasive imaging exam for the diagnosis and follow-up of spontaneous coronary artery dissection, by ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift today can have 5X the impact on AI research and technology. But hurry — the match challenge ends 9/19.